

**Enterprise P&T Meeting
Committee Meeting Minutes
October 24, 2022**

Voting Members Present

Batluck, David, DO	Feconda, Fury, PharmD	Murphy, Michelle, PharmD	Smith, Kirby, MD
Caton, Kirt, MD	Hockmuth, Robert, MD	Orr, Lavdena, MD	Weart, Wayne, PharmD
Cooper, Don, MD	Kryger, Emily, PharmD	Peters, Eric, PharmD	Whitfield, Rani, MD
Davis, Tracey, PharmD	Martin, Kelly, PharmD	Peterson, Andrew, PharmD	Wise, Rodney, MD
Elebra, Rogers, PharmD	Michael, Kendra, MD	Petkash, David, MD	

Excused Voting Members

Antypas, Christopher, PharmD	Brinley, Floyd (John), MD	Himmelstein, Bruce, MD
Beam, Donald, MD	Higgins, Lily, MD	Muller, Betty, MD

Invited Guests Present

Abad, Melissa, CPhT	Chan, Heidi	Kassim, Toks, PharmD	Seitz, Ally, PharmD
Amoroso, Linda	Cheely, George, MD	Meny, Christopher, PharmD	Smith, Bryan, MD
Baird, Bethany, CPhT	Cherian, Sheena, PharmD	Ng, Tammy, CPhT	Vodoor, Calla, PharmD
Broussard, Rachel	DeHoratius, Patrick, PharmD	Patel, Binal, PharmD	Weiss, Erich, PharmD
Carreras, Linda	Dick, Natalie, CPhT	Payne, Christine, Pharmacy Resident	Wiseman, Arlene, PharmD
Cavin, Allyssa	Guerriero, Monica	Plante, Jeanine, PharmD	

Issue	Discussion	Conclusion/Results	Action/ Person Responsible
1. Call to Order	The meeting was called to order at 6:01 PM EST Welcomed all external and internal participants.	Informational Only	Sheena Cherian
2. Conflict of Interest Disclosure	No conflicts announced	Informational Only	Sheena Cherian
3. BCC Positive Change		Informational Only	Chris Meny
4. DTM Program Description		Motion: Andrew Peterson Second: Donald Cooper	Binal Patel
5. Review and approval of July P&T and September proxy minutes		Informational Only Motion: Robert Hockmuth Second: Lavenda Orr	Sheena Cherian
6. Old Business			
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

7. New Business			
Anti-CD-19 CAR-T Immunotherapies	<p style="text-align: center;">PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p>	<p style="text-align: center;">Committee approved as recommended</p> <p>Motion: Robert Hockmuth Second: Kirby Smith</p>	<p style="text-align: center;">PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none">• Update initial authorization criteria for other forms of NHL to align with package insert and recent approvals for Breyanzi and Yescarta <p>[Redacted]</p>		
<p>[Redacted]</p>	<p>[Redacted]</p> <ul style="list-style-type: none">• [Redacted]• [Redacted]• [Redacted] <p>[Redacted]</p>	<p>[Redacted]</p> <p>[Redacted]</p>	<p>[Redacted]</p>


	<ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] ■ [REDACTED] 		
8. Drug Reviews:			
A. Therapeutic Class:			
COVID Test Kits	<p style="text-align: center;">PerformRx makes the following recommendation:</p> <ul style="list-style-type: none"> ■ [REDACTED] ■ [REDACTED] 	<p style="text-align: center;">Committee approved as recommended</p> <p>Motion: Kelly Martin Second: David Batluck</p>	No Changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• No changes to diagnostic agents in this class <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p>		
Vitamin C Products	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Kelly Martin Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none"> • Remove ascorbic acid 500 and 1500 mg ER tablet from formulary due to no utilization and alternative immediate release tablets available • Remove Emergen-C (ascorbic acid/multivitamins) 500 mg chewable tablet from formulary due to no utilization and availability of alternatives • Remove ascorbic acid/ascorbate sodium 500 mg oral wafer from formulary due to no utilization and alternative chewable tablets available <p>[REDACTED]</p>		
Pneumococcal Vaccines	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Kelly Martin Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>██████████/CHC:</p> <ul style="list-style-type: none">• Remove Prevnar 13 from the formulary as the CDC recommends the newer PCV15 or PCV20 instead for eligible adults• Increase the quantity limit of Pneumovax-23 to 2 doses per lifetime (1 mL) to account for patients with certain immunocompromised conditions requiring 2 doses if they were previously vaccinated with PCV13 <p>██████████</p> <p>██████████</p> <p>██████████</p>		
<p>██████████</p>	<p>██████████</p> <p>██████████</p> <p>██████████</p> <p>██████████</p>	<p>██████████</p> <p>██████████</p> <p>██████████</p>	<p>██████████</p>

			
B. Single Products:		:	

<p>Hyftor with PA Criteria</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Add Hyftor (sirolimus) to tier 4 of the formulary with a prior authorization requirement	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>
--------------------------------	--	--	--

	<ul style="list-style-type: none">• Approve the newly developed Topical mTOR kinase inhibitors prior authorization criteria <p>[Redacted]</p>		
Zynteglo with PA Criteria	<p>PerformRx makes the following recommendation:</p> <p>[Redacted]</p> <p>[Redacted]</p> <p>[Redacted]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

Amvuttra with PA Criteria

PerformRx makes the following recommendation:

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]

Committee approved as recommended

Motion: Kelly Martin
Second: Donald Cooper

PerformRx will update the criteria and formulary/PDL with any changes

	<p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Add Amvuttra (Vutrisiran) to tier 4 of the formulary with a prior authorization requirement• Approve the updated Transthyretin-mediated Amyloidosis Agents prior authorization criteria <p>[REDACTED]</p>		
<p>9. New Products</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Kirt Caton Second: David Batluck</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[REDACTED]

Add to the Specialty Tier with drug specific PA requirement for [REDACTED]/CHC:

- Orkambi

[REDACTED]

Add to the Specialty Tier with indication specific PA requirement for [REDACTED]/CHC [REDACTED]

- Velcade

Add to the Specialty Tier with indication specific PA requirement for [REDACTED]/CHC, [REDACTED]

- Carmustine

[REDACTED]

Add to the Specialty Tier with PA requirement for [REDACTED]/CHC [REDACTED]

- Skysona
- Xenpozyme






Remain non-formulary/non-preferred for [REDACTED]

[REDACTED] /CHC:

- ammonia N-13
- Bludigo
- CNJ-016 (National Stockpile)
- Curium US
- Cytalux
- Dyanavel XR
- Entadfi
- fluorodopa F-18
- Qwo
- Tauvid
- Tembexa
- Tpoxx
- Vivjoa 150 mg capsule

[REDACTED]

[REDACTED]

			
10. Prior Authorization Criteria Review			
A. Prior Authorization Criteria Annual Review			
			

<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>Brand Name Medication Criteria</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Require use of all available biosimilars <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Robert Hockmuth Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
Immune Globulins	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Kelly Martin Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• Update the criteria for chronic B-cell lymphocytic leukemia to require recurrent infection requiring IV antibiotics or hospitalization to align with current guidelines• Update criteria for bone marrow transplantation to require bacteremia or recurrent sinopulmonary infections to align with current guidelines• Language changes for clarity <p>[REDACTED]</p>		
--	--	--	--

	<ul style="list-style-type: none">[REDACTED][REDACTED]		
[REDACTED]	<ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED]	<ul style="list-style-type: none">[REDACTED][REDACTED]	[REDACTED]
Safety Edit Exception Criteria	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED]	<p>Committee approved as recommended</p> <p>Motion: Kelly Martin Second: Donald Cooper</p>	<p>PerformRx will update the criteria language for ACLA</p> <p>No Other Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• Approve the Safety Edit Exception Criteria with no changes <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

<p>Sleep Disorder Therapy</p>	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none">■ [Redacted]■ [Redacted]■ [Redacted]■ [Redacted]■ [Redacted] <p>■ [Redacted]</p> <ul style="list-style-type: none">■ [Redacted]■ [Redacted]■ [Redacted]	<p>Committee approved as recommended</p> <p>Motion: Kelly Martin Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>
-------------------------------	---	---	--

█
█
█
█

█
█

█
█
█

█
█
█

█
█
█

█/CHC:

- Add exclusion criteria of succinic semialdehyde dehydrogenase deficiency for Xyrem/Xyway to align with package insert
- Remove requirement for documentation member has been referred for substance abuse disorder treatment if a member has a history of substance abuse as this is

addressed in the REMS program for
Xyrem/Xyway

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p>		
Stimate	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]/CHC:</p> <ul style="list-style-type: none">• Update title to Desmopressin nasal spray as Stimate is not currently available• Specifying this policy only applies to the 1.5 mg/mL strength of desmopressin nasal spray• Allow approval of a single unit of desmopressin nasal spray to allow for a trial	<p>Committee approved as recommended</p> <p>Motion: Kelly Martin Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>in those with a diagnosis of mild to moderate Type 2A, 2M, or 2N von Willebrand's disease</p> <p>[REDACTED]</p>		
<p>Sublingual Allergenic Extracts</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• Clarify requests for allergenic extracts can be used to treat allergic rhinitis with or without conjunctivitis <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
Zulresso	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Kirt Caton Second: Robert Hockmuth</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>██████████/CHC:</p> <ul style="list-style-type: none">• Lower age limit to align with updated package insert <p>██████████</p> <p>██</p>		
<p>██████████</p>	<p>██████████</p> <p>██</p> <p>██████████</p> <p>██</p>	<p>██████████</p> <p>████████████████████</p>	<p>██████████</p> <p>████████████████████</p>
<p>██████████</p>	<p>██████████</p> <p>██</p> <p>██████████</p> <p>██</p> <p>██████████</p> <p>██</p> <p>██████████</p> <p>██</p>	<p>██████████</p> <p>████████████████████</p>	<p>██████████</p> <p>████████████████████</p>

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
B. Prior Authorization Criteria Annual Review without Clinical Changes			
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
[REDACTED]	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
Danazol	PerformRx makes the following recommendation:	Committee approved as recommended	No Changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none"> • Approve the prior authorization criteria with no changes <p>[REDACTED]</p>	<p>Motion: David Batluck Second: Donald Cooper</p>	
<p>Daraprim (pyrimethamine)</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>No Changes</p>

	<p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the prior authorization criteria with no changes <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>Fabrazyme</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the prior authorization criteria with no changes <p>[REDACTED]</p>		
Galafold (migalastat)	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the prior authorization criteria with no changes <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	No Changes

<p>Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none"> • Approve the prior authorization criteria with no changes <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>No Changes</p>
<p>Oncology Drugs</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>No Changes</p>






	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] CHC:</p> <ul style="list-style-type: none">• Approve the prior authorization criteria with no changes <p>[REDACTED]</p>		
Prior Authorization Exception Criteria	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	No Changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none"> • Approve the prior authorization criteria with no changes <p>[REDACTED]</p>		
<p>Quantity Limit Exception Criteria</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>CHC:</p> <ul style="list-style-type: none">• Approve the prior authorization criteria with no changes <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>[REDACTED]</p>		
<p>Step Therapy Exception Criteria</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none"> • Approve the prior authorization criteria with no changes <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>No Changes</p>
<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>	<p>[REDACTED]</p>

	<ul style="list-style-type: none">• [REDACTED]	[REDACTED]	
Type I Interferon (IFN) Receptor Antagonist	<p>PerformRx makes the following recommendation:</p> <ul style="list-style-type: none">[REDACTED][REDACTED][REDACTED][REDACTED][REDACTED] <p>[REDACTED] /CHC:</p> <ul style="list-style-type: none">• Approve the prior authorization criteria with no changes <ul style="list-style-type: none">[REDACTED]	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	No Changes

			
Zolgensma	<p>PerformRx makes the following recommendation:</p> 	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	No Changes

	<p>██████/CHC:</p> <ul style="list-style-type: none">Approve the prior authorization criteria with no changes <p>██████</p>		
<p>██████/CHC - Reblozyl</p>	<p>PerformRx makes the following recommendation:</p> <p>██████/CHC:</p> <ul style="list-style-type: none">Approve the prior authorization criteria with no changes	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>No Changes</p>
<p>████████████████████</p>	<p>████████████████████</p> <p>██████</p>	<p>████████████████████</p> <p>████████████████████</p>	<p>████████</p>
<p>████████████████</p>	<p>████████████████████</p> <p>██████</p>	<p>████████████████████</p> <p>████████████████████</p>	<p>████████</p>
<p>████████████████████</p>			

<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>
<p>11. Recalls</p>	<p>7/8/2022 –10/13/2022</p> <p>Vi-Jon, LLC Expands Voluntary Nationwide Recall of All Flavors and Lots Within Expiry of Magnesium Citrate Saline Laxative Oral Solution Due to Microbial Contamination</p>	<p>Informational</p>	<p>PerformRx</p>
<p>12. Adjourn</p>	<p>The meeting adjourned at 7:39</p>	<p>N/A</p>	<p>Sheena Cherian</p>
	<p>The next meeting January 30th, 2023</p>		



Bruce Himelstein, MD MBA
SVP, Medical Officer

February 3, 2023

